Publications

image description
Access publications
The Open Archives of the University of Geneva constitute a dynamic digital platform which plays an essential role in the dissemination and preservation of the intellectual production of the institution. This initiative is part of the desire to promote free access to knowledge and promote the visibility of research work carried out within the university.

2024

  • Ramzy GM, Meister I, Boccard J, Rudaz S, Nowak-Sliwinska P, Caracterization of the lipid landscape in FOLFOXIRI-resistant colorectal cancer cells, under review

  • Schelker C, Revaclier L, Simula L, Benboubker B, Borchard G, Nowak-Sliwinska P, Liposomal Tubacin: strategies for the formulation of a highly hydrophobic anticancer drug, under review

  • Kowolik E, Szczygieł D, Szczygieł M, Drzał A, Vemuri K, Olsson AK, Griffioen AW, Nowak-Sliwinska P, Wolnicka-Glubisz A and Elas M, Preclinical AGUIX® Theranostic Nanoparticles for PDT Tar-get-ing Blood Vessels Cancers,in press, 2024 (IF 4.5)

  • Benboubker V, Ramzy GM, Jacobs S, Nowak-Sliwinska P, Challenges in validation of combination treatment strategies for CRC using patient-derived organoids, J Exp Clin Cancer Res, 2024 Sep 11;43(1):259. doi: 10.1186/s13046-024-03173-x (IF 12.66)

  • Gubala J, Mieville V, Benamran D, Valerio M, Tille JC, Nowak-Sliwinska P, Generation and maintenance of kidney and kidney cancer organoids from patient-derived material for drug development and precision oncology, Molecular Therapy – Methods & Clinical Development, 2024, doi.org/10.1016/j.omtm.2024.101368 (IF 4.66)

  • Zebret S, Hadiji M, Romano-deGea J, Bornet A, Ortiz D, Fadaei TD, Stathopoulos C, Nowak-Sliwinska P, Munier F, Dyson PJ, New melphalan derivatives for the treatment of retinoblastoma in combination with thermotherapy,RSC Med. Chem., 2024, 15, 2300. doi: 10.1039/d4md00211c (IF 4.1)

  • Dugershaw-Kurzer B, Bossart J, Buljan M, Hannig Y, Zehnder S, Gupta GS, Kissling VS, Nowak-Sliwinska P, van Beijnum JR, Griffioen AW, Masjosthusmann S, Zühr E, Fritsche E, Hornung R, Rduch T, Buerki-Thurnherr T, Uncovering the role of nanoparticles in disrupting placental secretome and its consequences on angiogenesis and neurodevelopment, Advanced Science.(2024) May 20:e2401060. doi: 10.1002/advs.202401060 (IF 15.4)

2023

  • Poinot H, Dupuychaffray E, Arnoux G, Alvarez M, Tachet J, Ezzar O, Moore J, Bejuy O, Olesti E, Gonzalez Ruiz V, Rudaz S, Tille J-C, Vögel C, NowakSliwinska P, Bourquin C, Pommier A, Activation of endogenous glucocorticoids by HSD11B1 inhibits the antitumor immune response in renal cancer, Oncoimmunology. 2023 Nov 30;13(1):2286820. doi: 10.1080/2162402X.2023.2286820 (IF 7.72)

  • Nowak-Sliwinska P, Griffioen AW, Rising impact of cell death research, Apoptosis, (2023), 28(11-12):1503-1504. doi: 10.1007/s10495-023-01895-5 (IF 7.21)

  • Mieville V, Griffioen AW, Benamran D, Nowak-Sliwinska P, Advanced in vitro models for renal cell carcinoma therapy design, Biochem Biophys Acta Rev Cancer, (2023)1878(5):188942, doi: 10.1016/j.bbcan.2023.188942 (IF 11.41)

  • Ramzy GM, Norkin M, Koessler T, Voirol L, Tihy M, Hany D, McKee T, Ris F, Buchs N, Docquier M, Toso C, Rubbia-Brandt L, Bakalli G, Guerrier S, Huelsken J, Nowak-Sliwinska P, Platform conbining mathematical modeling and patient-derived organoids to facilitate personalized treatment of colorectal carcinoma, Journal of Experimental & Clinical Cancer Research, (2023) 42:79, doi.org/10.1186/s13046-023-02650-z (IF 12.66)

  • Schelker C, Nowak-Sliwinska P, Borchard G, Liposomal delivery systems for drug combinations in cancer treatment, Journal of Controlled Release, (2023) 358:59-77, doi: 10.1016/j.jconrel.2023.04.006 (IF 11.47)

  • Hany D, Zoetemelk M, Bhattacharya K, Nowak-Sliwinska P, Picard D, Network-informed discovery of multidrug combinations forERα+/HER2-/PI3Kα-mutant breast cancer, Cell Mol Life Sci. 2023 Mar 3;80(3):80. doi: 10.1007/s00018-023-04730-x (IF 9.78)

  • Nowak-SliwinskA P, van Beijnum JR, Griffioen JR, Huinen ZR, Grima Sopesens N, Schulz R, Jenkins SV, RPM Dings, Groenendijk FH, Huijbers EJM, Thijssen V, Jonasch E, Vyth-Dreese FA, Jordanova ES, Bex A, Bernards R, de Gruijl TD, Griffioen AW, Proinflammatory activity of VEGF-targeted treatment through reversal of tumor endothelial cell anergy, Angiogenesis, (2023) 26(2):279-293, doi: 10.1007/s10456-022-09863-4 (IF 10.66)

2022

  • van Beijnum JR, Huijbers EJM, van Loon K, Akbari P, Roos A, Wong TJ, Jimenez C, Nowak-Sliwinska P, Griffioen AW*, Extracellular vimentin mimics VEGF and is a target for anti-angiogenic immunotherapy, Nature Commun, 3(1):2842.2022, doi: 10.1038/s41467-022-30063-7. (IF 17.69)
  • Ramzy GM , Boschung L, Koessler T, Delucinge-Vivier C,  Docquier M,  McKee TA, Rubbia-Brandt L, Nowak-Sliwinska P, FOLFOXIRI Resistance Induction and Characterization in Human Colorectal Cancer Cells, Cancers, 2022, 14(19):4812. doi: 10.3390/cancers14194812. (IF 6.64)
  • Griffioen AW, Nowak-Sliwinska P, Programmed cell death lives, Apoptosis, 27(9-10):619-621, 2022. doi: 10.1007/s10495-022-01758-5. (IF 4.68)

2021

  • Rausch M, Rutz A, Allard PM, Delucinge-Vivier C, Docquier M, Dormond O, Dyson PJ, Wolfender JL, Nowak-Sliwinska P, Drug Repurposing to Identify a Synergistic High-Order Drug Combination to Treat Sunitinib-Resistant Renal Cell Carcinoma, Cancers, 13(16):3978. 2021, doi:10.3390/cancers13163978.(IF 6.64)
  • Rausch M, Rutz A, Allard PM, Delucinge-Vivier C, Docquier M, Dormond O, Wolfender JL, Nowak-Sliwinska P. Molecular and Functional Analysis of Sunitinib-Resistance Induction in Human Renal Cell Carcinoma Cells, Int J Mol Sci, 22(12):6467. 2021, doi: 10.3390/ijms22126467. (IF 5.92)
  • Smadja DM, Mentzer SJ, Fontenay M, Laffan MA, Ackermann M, Helms J, Jonigk D, Chocron R, Pier GB, Gendron N, Pons S, Diehl JL, Margadant C, Guerin C, Huijbers EJM, Philippe A, Chapuis N, Nowak-Sliwinska P, Karagiannidis C, Sanchez O, Kümpers P, Skurnik D, Randi AM, Griffioen AW., COVID-19 is a systemic vascular hemopathy: insight for mechanistic and clinical aspects, Angiogenesis, 2021, 4(4):755-788. doi: 10.1007/s10456-021-09805-6 (IF 9.59)
  • Huinen ZR, Huijbers EJM, van Beijnum JR, Nowak-Sliwinska P, Griffioen AW, Anti-angiogenics overcome tumor endothelial cell anergy and improve immunotherapy outcomes,  Nature Reviews in Clinical Oncol__ogy, 2021, DOI:10.1038/s41571-021-00496- y (IF 66.6)
  • Rausch M,  Blanc L, De Souse Silva O, Dormond O, Griffioen AW, Nowak-Sliwinska P, Characterization of renal cell carcinoma heterotypic 3D co-cultures with immune cell subsets, Cancers, 2021, 13(11), 2551; DOI: 10.3390/cancers13112551 (IF 6.64)
  • Ducrey E, Castrogiovanni C, Meraldi P, Nowak-Sliwinska P,  Forcing dividing cancer cells to die; low-dose drug combinations to prevent spindle pole clustering, Apoptosis, 26(5-6):248-252, 2021, DOI:10.1007/s10495-021-01671-3 (IF 4.54)
  • Griffioen AW, Nowak-Sliwinska P, A quarter century of Apoptosis, Apoptosis, 26(5-6):233-234, 2021, DOI: 10.1007/s10495-021-01672-2 (IF 4.54)

 2020

  • RA de Boer, J-S Hulot, CG Tocchetti, JP Aboumsallem, P Ameri, SD Anker, J Bauersachs, E Bertero, AAJ Coats, J Čelutkienė, O Chioncel, P Dodion, T Eschenhagen, D Farmakis, A Bayes-Genis, D Jäger, EA Jankowska, RN Kitsis, SH Konety, J Larkin, L Lehmann, DJ Lenihan, C Maack, J Moslehi, OJ Müller, P Nowak-Sliwinska, MF Piepoli, P Ponikowski, R Pudil, PP. Rainer, F Ruschitzka, D Sawyer, PM Seferovic, T Suter, T Thum, P van der Meer, LW Van Laake, S Von Haehling, S Heymans, AR Lyon, J Backs;  Common Mechanistic Pathways in Cancer and Heart Failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC), European Journal of Heart Failure, 22(12), 2272-2289, 2020, doi: 10.1002/ejhf.2029. (IF 11.6)
  • Rausch M, Weiss A, Zoetemelk M, Piersma SR, Jimenez CR, van Beijnum JR, Nowak-Sliwinska P, Optimized combination of HDACI and TKI efficiently inhibits metabolic activity in renal cell carcinoma and overcomes sunitinib-resistance,  Cancers, 12(11):E3172. doi: 10.3390/cancers121131722020. (IF 6.13)
  • van Beijnum JR, Weiss A, Berndsen RH , Wong TJ, Reckman LC, Piersma SR, Zoetemelk M, de Haas RR, Dormond O, Bex A, Henneman AA, Jimenez CR, Griffioen AW, Nowak-Sliwinska P, Integrating phenotypic search and phosphoproteomic profiling of active kinases for optimization of drug mixtures for RCC treatment, Cancers, 12(9), 2697; doi.org/10.3390/cancers12092697, 2020. (IF 6.13)
  • Zoetemelk M, Ramzy GM, Rausch M, Koessler T, van Beijnum JR,  Weiss A, Mieville V, Piersma SR, de Haas RR, Delucinge-Vivier C, Andres A, Toso C, Henneman AA, Ragusa S, Petrova TV, Docquier M, McKee TA, Jimenez CR, Daali Y, Griffioen AW, Rubbia-Brandt L, Dietrich PY, Nowak-Sliwinska P, Optimized high-order low-dose drug mixtures boost selectivity and efficacy of colorectal carcinoma treatment, Molecular Oncology, doi: 10.1002/1878-0261.12797, 2020. (IF 6.54)
  • Zoetemelk M, Ramzy GM, Rausch M, Nowak-Sliwinska P, Drug-drug interactions of irinotecan, 5-fluorouracil, folinic acid and oxaliplatin in colorectal carcinoma treatment_, Molecules,_ 25, 2614; doi:10.3390/molecules25112614_,_ 2020. (IF 3.06)
  • Ramzy GM, Koessler T, Ducrey E, McKee T, Ris F, Buchs N, Rubbia-Brandt L, Dietrich PY, Nowak-Sliwinska P, Patient-derived in vitro models for drug discovery in colorectal carcinoma, Cancers, 2(6):1423_,_ 2020. (IF 6.13)
  • Rausch M, Weiss A, Akchanian J, Rotari A, Nowak-Sliwinska P, Identification of low-dose multidrug combinations for sunitinib naïve and pre-treated renal cell carcinoma, Br J Cancer, 123(4):556-567_,_ 2020. doi: 10.1038/s41416-020-0890-y. (IF 5.42)
  • Nowak-Sliwinska P, Griffioen AW. Programmed death, cells on the last train to glory, Apoptosis. 2020 Apr;25(3-4):151-153, 2020. (IF 4.54)
  • Nowak-Sliwinska P, Optimization for multidrug combinations: Challenges and perspectives in complex disorders. Pharmacol Res. 154:104165, 2020. (IF 5.89)

 2019

  • Berndsen BH, Swier N , van Beijnum JR, Nowak-Sliwinska P, Colorectal cancer growth retardation through induction of apoptosis, using an optimized synergistic cocktail of axitinib, erlotinib and dasatinib, Cancers, 11(12):1878, 2019. (IF 6.13)
  • Weiss A, Le Roux-Bourdieu M,  Zoetemelk M, Ramzy GM, Harry D, Miljkovic-Licina M, Falamaki K, Wehrle-Haller B, Meraldi P, Nowak-Sliwinska P, Identification of a Synergistic Multi-Drug Combination Active in Cancer Cells via the Prevention of Spindle Pole Clustering, Cancers, 11(10):1612, 2019. (IF 6.13)
  • Yetkin-Arik B, Vogels I, Nowak-Sliwinska P, Weiss A, Houtkooper R, Van Noorden CJF, Klaassen I, Schlingemann RO, The role of glycolysis and mitochondrial respiration in the formation and functioning of endothelial tip cells during angiogenesis, Scientific Reports, 30;9(1):12608, 2019. (IF 4.12)
  • Renfrew AK, Karges J Scopelliti R, Bobbink FD, Nowak-Sliwinska P, Gasser G, Dyson PJ, Towards Light Activated Ruthenium-Arene (RAPTA-type) Prodrug Candidates, ChemBioChem, 20(22):2876-2882, 2019. (IF 3.06)
  • Rausch R, Dyson PJ, Nowak-Sliwinska P, Recent Considerations in the Application of RAPTA-C for cancer treatment and perspectives for its combination with immunotherapies_, Adv Therapeutics,_ 2 (9), 1900042, DOI: 10.1002/adtp.201900042, 2019. (awaiting IF)
  • Berndsen B,  Castrogiovanni C, Weiss A, Rausch R, Dallinga M, Miljkovic-Licina M, Klaassen I, Meraldi M, van Beijnum J, Nowak-Sliwinska P, Anti-angiogenic effects of crenolanib are mediated by mitotic modulation independently of PDGFR expression, Br J Cancer, 121(2):139-149, 2019. (IF 5.92)
  • Nowak-Sliwinska P, Scapozza L, Riuz i Altaba A, Drug repurposing in oncology: compounds, pathways, phenotypes and computational approaches for colorectal cancer, BBA Reviews on Cancer, 1871(2):434-454, 2019. (IF 8.22)
  • Zoetemelk M, Rausch M, Colin D, Dormond O, Nowak-Sliwinska P, Short-term 3D culture systems of various complexity for treatment optimization of colorectal carcinoma, Nature Sci Reports, 9(1):7103_,_ 2019. (IF 4.12)
  • Griffioen AW, Nowak-Sliwinska P, Cell death rocks. Apoptosis, 24(3-4):205-207, 2019. (IF 4.05)
  • Nowak-Sliwinska P, Van Beijnum JR, Huijbers EJM, Gasull PC, Mans L, Bex A and Griffioen AW. Oncofetal insulin receptor isoform A marks the tumor endothelium; an underestimated pathway during tumor angiogenesis and angiostatic treatment. Br J Cancer, 120(2):218-228, 2019. (IF 5.92)

 2018

  • Thijssen VL, Paulis YV, Nowak-Sliwinska P, Deumelandt et al, Targeting PDGF-mediated recruitment of pericytes blocks vascular mimicry and tumor growth., J Pathol, 246(4):447-458. (IF 6.89)
  • Dallinga MG, Yetkin-Arik B, Kayser RP, Vogels, IMC, Nowak-Sliwinska P, Griffioen AW, van Noorden CJF, Klaassen I, Schlingemann RO, IGF2 and IGF1R identified as novel tip cell genes in primary microvascular endothelial cell monolayers, Angiogenesis, 21(4):823-836. (IF: 5.25)
  • Nowak-Sliwinska P, Griffioen AW. Apoptosis on the move, Apoptosis. 2018 Jun;23(5-6):251-254. (IF 3.83)
  • Nowak-Sliwinska P, Alitalo K, Allen E, Anisimov A, Aplin AC, Auerbach R, Augustin HG, Bates DO, van Beijnum JR, Bender RHF, Bergers G, Bikfalvi A, Bischoff J, Böck BC, Brooks PC, Bussolino F, Cakir B, Carmeliet P, Castranova D, Cimpean AM, Cleaver O, Coukos G, Davis GE, De Palma  M, Dimberg A, Dings RPM, Djonov V, Dudley AC, Dufton NP, Fendt SM, Ferrara N, Fruttiger M, Fukumura D, Ghesquière B, Gong Y, Griffin RJ, Harris AL,  Hughes CCW, Hultgren NW, Iruela-Arispe L, Irving M, Jain RK, Kalluri R, Kalucka J, Kerbel RS, Kitajewski J, Klaassen I, Kleinmann HK, Koolwijk P, Kuczynski E, Kwak BR, Marien K, Melero-Martin JM, Munn LL, Nicosia RF, Noel A, Nurro J, Olsson AK, Petrova TV, Pietras K, Pili R, Pollard JW, Post JM, Quax PHA, Rabinovich GA, Raica M, Randi AM, Ribatti D, Ruegg C, Schlingemann RO, Schulte-Merker S, Smith LEH, Song JW, Stacker SA, Stalin J, Stratman AN, Van de Velde M, van Hinsbergh VWM, Vermeulen PB, Waltenberger J, Weinstein BM, Xin H, Yetkin-Arik B, Yla-Herttuala S, Yoder MC, Griffioen AW. Consensus guidelines for the use and interpretation of angiogenesis assays.  Angiogenesis. 2018, 21(3), 425-532 (IF 5.2).
  • Huijbers EJM, van Beijnum JR, Lê CT, Langman S, Nowak-Sliwinska P, Mayo KH, Griffioen AW. An improved conjugate vaccine technology; induction of antibody responses to the tumor vasculature. Vaccine. 2018, 36(21):3054-3060 (IF 3.2).
  • Lee KGZ, Babak MV, Weiss A, Dyson PJ, Nowak-Sliwinska P*, Montagner D*, Ang WH. Development of an Efficient Dual-action GST-inhibiting Anticancer Platinum(IV) Prodrug. ChemMedChem, 2018, 13(12):1210-1217 (IF 3.2).

 2017

  • van Beijnum JR, Nowak-Sliwinska P, van Berkel M, Wong TJ, Griffioen AW.A genomic screen for angiosuppressor genes in the tumor endothelium identifies a multifaceted angiostatic role for bromodomain containing 7 (BRD7). Angiogenesis. 2017 Nov;20(4):641-654, 2017 (IF 5.2).
  • Griffioen AW, Nowak-Sliwinska P. Apoptosis turns 21, Apoptosis Dec;22(12):1485-1486, 2017 (IF 3.8).
  • Nowak-Sliwinska P, Griffioen AW, Angiogenesis inhibitors in combinatorial approaches, Angiogenesis, 20(2):183-184, 2017 (IF 5.2).
  • van Beijnum JR, Pieters W, Nowak-Sliwinska P, Griffioen AW, Insulin-like growth factor axis targeting in cancer and tumor angiogenesis – the missing link, Biological Reviews, Biol Rev Camb Philos Soc. Aug;92(3):1755-1768 (IF 9.67).
  • Nowak-Sliwinska P, Griffioen AW, Angiogenesis inhibitors in combinatorial approaches, Angiogenesis, 20(2):183-184, 2017 (IF 5.2).
  • Kucinska M, Murias M, Nowak-Sliwinska P, Beyond mouse cancer models: three-dimensional human-relevant in vitro and non-mammalian in vivo models for photodynamic therapy, Mutation Research, Jul;773:242-262, 2017 (IF 5.49).
  • Gasser-Weiss P, Nowak-Sliwinska P, Current trends in multidrug optimization: an alley of future successful treatment of complex disorders, SLAS Technol. 2017 Jun;22(3):254-275.
  • Berndsen B, Abdul UK, Weiss A, Zoetemelk M, Te Winkel MT, Dyson PJ, Griffioen AW, Nowak-Sliwinska P. Epigenetic approach for angiostatic therapy; promising combinations for cancer treatment. Angiogenesis, 20(2):245-267, 2017 (IF 5.2).
  • van Beijnum JR, Giovanetti E, Poel D, Nowak-Sliwinska P, Griffioen AW, miRNAs: microManagers of anti-cancer combination therapies, Angiogenesis, 20(2):269-285_,_ 2017 (IF 5.2).
  • Berndsen RH, Weiss A, Abdul UK, Wong TJ, Meraldi P, Griffioen AW, Dyson PJ and Nowak-Sliwinska P, Combination of ruthenium(II)-arene complex [Ru(ɳ6-p-cymene)Cl2(pta)] (RAPTA-C) and the epidermal growth factor receptor inhibitor erlotinib results in efficient angiostatic and antitumor activity, Scientific Reports, 7:43005. doi: 10.1038/srep43005, 2017 (IF 5.228).

2016

  • van Beijnum JR, Thijssen VL, Läppchen T, Wong , Verel I, Engbersen M, Schulkens IJ, Rossin R, Grüll H, Griffioen AW, and Nowak-Sliwinska P, A key   role   for galectin-1 in sprouting angiogenesis revealed by novel rationally designed antibodies, International Journal of Cancer, 139(4):824-35, 2016 (IF 5.085).
  • Stibal D, Therrien B, Süss-Fink G, Nowak-Sliwinska P, Dyson PJ, Čermáková E, Řezáčová M, Tomšík P, Chlorambucil conjugates of dinuclear p-cymene ruthenium trithiolato complexes as dual target anticancer compounds_,_ Journal of Biological Inorganic Chemistry_,_ 21(4):443-52_, 2016_ (IF 2.538).
  • Nowak-Sliwinska P, Ding X, Weiss A, Dyson PJ, van den Bergh H, Griffioen AW, Ho CM*, The Feedback System Control technique, an ultra-efficient drug combination screening method, Nature Protocols, 11(2):302-15_,_ 2016, (IF 9.673) Invited paper.
  • Huijbers EJM, Sabrkhany S, van Beijnum JR, Thijssen VL, Nowak-Sliwinska P and Griffioen AW, The tumor stromal microenvironment in resistance to anti-angiogenic therapy, Drug Resistance Updates, 25:26-37, 2016 (IF 9.121). Equal contribution of all authors.
  • Nowak-Sliwinska P and Griffioen AW, Therapeutic potential of angiogenesis inhibitor mixtures in cancer treatment, Research and Clinical Medicine, in press, 2016. Invited review**.**

2015       

  • Weiss A, Berndsen RH, Ding X, Ho CH, Dyson PJ, van den Bergh H, Griffioen AW, and Nowak-Sliwinska   P, A streamlined search technology for identification of synergistic drug combinations, Scientific Reports, 5:14508, 2015 (IF 5.578).
  • Clavel CM, Nowak-Sliwinska P, Păunescu E, and Dyson PJ, Thermoresponsive fluorinated small-molecule based drugs; a new concept in efficient local targeted chemotherapy, ChemMedComm, 6(12):2054–2062, 2015_._ (IF 2.495)
  • van Beijnum JR, Nowak-Sliwinska P, Huijbers EJM, Thijssen VL, and Griffioen AW, The great escape; hallmarks of resistance to angiogenesis inhibition. Pharmacological Reviews, 67(2):441-61, 2015 (IF 18.55). Invited review**.** Equal contribution of all authors.
  • Weiss A, Ding X, van Beijnum JR, Wong I, Wong TJ, Berndsen RH, Dormond O, Ho CH, Dyson PJ, van den Bergh H, Griffioen AW, and Nowak-Sliwinska P, Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer, Angiogenesis, 18(3):233-44_,_ 2015, (IF 4.876).
  • Păunescu E, Nowak-Sliwinska P, Clavel CM, Scopelliti R, Griffioen AW, Dyson PJ*, Anticancer Organometallic Osmium(II)-p-cymene Complexes, ChemMedChem, 10(9):1539-47, 2015 (IF 2.98). This paper was selected for delivery of the back cover image.
  • Nowak-Sliwinska P, Clavel CM, Păunescu E, te Winkel MT, Griffioen AW, Dyson PJ*, Pendant perfluorous chains tailor specific anti-angiogenic or anti-cancer activity of bifunctional ruthenium(II)-p-cymene complexes, Molecular Pharmaceuticals, 12(8):3089-96, 2015 (IF 4.384).
  • Clavel CM, Nowak-Sliwinska P, Păunescu E, Griffioen AW, and Dyson PJ*, In vivo evaluation of small-molecule thermoresponsive-designed anticancer drugs, Chemical Science 6, 2795 – 2801, 2015. (IF 9.211)
  • Clavel CM, Păunescu E, Nowak-Sliwinska P, Griffioen AW, Scopelliti R and Dyson PJ*, Modulating the Anticancer Activity of Ruthenium(II)-arene Complexes, Journal of Medicinal Chemistry, 58(8):3356-65, 2015. (IF 5.61).  
  • Nowak-Sliwinska P, Weiss A, van Beijnum JR, Wong TH, Kilarski WW, Szewczyk G, Verheul HMV, Sarna T, van den Bergh H and Griffioen AW*, Photoactivation of lysosomally sequestered sunitinib after angiostatic treatment causes vascular occlusion and enhances tumor growth inhibition, Cell Death Disease, 12;6:e1641, 2015. (IF 5.177)
  • Weiss A, Bonvin D, Berndsen RH, Scherrer E, Wong TJ, Dyson PJ, Griffioen AW, and Nowak-Sliwinska P, Angiostatic treatment prior to chemo- or photodynamic therapy improves anti-tumor efficacy, Scientific Reports, 5:8990, 2015. (IF 5.57)
  • Gupta G, Nowak-Sliwinska P, Herrero N, Dyson PJ, Therrien B, Increasing the Selectivity of Biologically Active Tetranuclear Arene Ruthenium Assemblies, Journal of Organometallic Chemistry, doi:10.1016/j.jorganchem.2015.02.004, 2015. (IF 2.31)
  • Păunescu E, Clavel CM, Nowak-Sliwinska P, Griffioen AW, and Dyson PJ, Improved angiostatic activity of Dasatinib by modulation with hydrophobic chains, ASC Medicinal Chemistry Letters, 6(3):313-317, 2015. (IF 3.07)
  • van den Bergh H, and Nowak-Sliwinska P, On the use of photodynamic therapy in the treatment of polypoidalchoroidal vasculopathy: an update, in Handbook of Photodynamic Therapy : Updates on Recent Applications of Porphyrin-Based Compounds, R. Pandey, D. Kessel, T.J. Dougherty (Ed), World Scientific Publishing Co Pte Ltd., Singapore, ISBN13 9789814719643, 2016

2014

  • Ding X, Liu W, Weiss A, Li Y, Wong I, Griffioen AW, van den Bergh H, Nowak-Sliwinska P, Ho C-M, Discovery of A Low Order Drug-Cell Response Surface for Applications to Personalized Medicine, Physical Biology 11(6):065003, 2014. (IF 3.14)
  • Weiss A, Berndsen RH, Dubois M, Müller C, Schibli R, Griffioen AW, Dyson PJ and Nowak-Sliwinska P_,_ In vivo anti-tumor activity of the organometallic ruthenium(II)-arene complex [Ru(ɳ6-p-cymene)Cl2(pta)] (RAPTA-C) in human ovarian and colorectal carcinomas, Chemical Science, 5, 474, 2014.(IF 9.144)
  • Gupta G, Nowak-Sliwinska P, Herrero N, Dyson PJ, Therrien B, Highly Water Soluble Trithiolato-bridged Dinuclear Arene Ruthenium Complexes, Inorganica Chimica Acta, 423:524-529, 2014. (IF 2.04)
  • Huntosova V, Gay S, Nowak-Sliwinska P, Kumar SR, van den Bergh H, Zellweger M and Wagnieres G, In Vivo Measurement of Tissue Oxygenation by Time-resolved Luminescence Spectroscopy: Advantageous properties of dichlorotris(1,10-phenantroline)-Ruthenium(II) hydrate (Ru(Phen)), Journal of Biomedical Optics, 19(7):77004_,_ 2014. (IF 2.88)    
  • Clavel CM, Păunescu E, Nowak-Sliwinska P, Griffioen AW, Scopellity R and Dyson PJ, Discovery of a Highly Tumor-selective Organometallic Ruthenium(II)-Arene Complex, Journal of Medicinal Chemistry, 57(8):3546-58, 2014. (IF 5.61)
  • Clavel CM, Păunescu E, Nowak-Sliwinska P and Dyson PJ, Thermoresponsive Organometallic Arene Ruthenium Complexes for Tumour Targeting, Chemical Science, 5, 1097-1101_,_ 2014_._ (IF 8.6)
  • Weiss A, van Beijnum JR, Bonvin D, Jichlinski P, Dyson PJ, Griffioen AW and Nowak-Sliwinska P, Low-dose angiostatic tyrosine kinase inhibitors improve photodynamic therapy for cancer: lack of vascular normalization, Journal of Cellular and Molecular Medicine, 18(3):480-91, 2014. (IF 4.75)
  • Kilarski WW, Muchowicz A, Wachowska M, Mężyk-Kopeć R, Golab J, Swartz MA and Nowak-Sliwinska P, Optimization and regeneration kinetics of lymphatic-specific photodynamic therapy in the mouse dermis, Angiogenesis, 7(2):347-57, 2014_._ (IF 4.41). This paper was selected for delivery of the front cover image.
  • Griffioen AW, Weiss A, Berndsen RH, Abdul UK, te Winkel MT and Nowak-Sliwinska P, The emerging quest for the optimal angiostatic combination therapy, Biochemical Society Transactions, 42(6):1608-1615, 2014. (IF 3.24)
  • Nowak-Sliwinska P, Segurea T and Iruela-Arispe ML, The chicken chorioallantoic membrane model in biology, medicine and bioengineering, Angiogenesis, 17(4):779-804, 2014_, invited review_ (IF 4.41). This paper was selected for delivery of the cover image.

2013

  • Nowak-Sliwinska P*, van den Bergh H, Sickenberg M and Koh AHC, Photodynamic Therapy for Polypoidal Choroidal Vasculopathy, Progres in Retinal and Eye Research, 37, 182-199, 2013**. (IF 9.9_)_**  This article was written by invitation of the Editor-in-Chief of Progress in Retinal and Eye Research
  • Nowak-Sliwinska P*, Weiss A, Sickenberg M, Griffioen AW and van den Bergh H, The role of photodynamic therapy in malignant and non-malignant eye disorders, Journal of Analytical and Bioanalytical Technology S1: 007, 2013. (IF 3.48)
  • van Wijk XM, Thijssen VL, Lawrence R, van den Broek SA, Dona M, Naidu N, Oosterhof A, de Westerlo EM, Kusters LJ, Khaled Y, Jokela TA, Nowak-Sliwinska P, Kremer H, Stringer SE, Griffioen AW, van Wijk E, van Delft FL and van Kuppevelt TH*, A pleiotropically acting GlcNAc analog interferes with UDP-GlcNAc metabolism, heparan sulfate expression, and angiogenesis in vivo, ACS Chemical Biology 18;8(10):2331-8, 2013. (IF 5.4)
  • Nazarov A, Baquié M, Nowak-Sliwinska P*, Zava O, van Beijnum JR, Groessl M, Chisholm DM, Ahmadi Z, McIndoe SJ, Griffioen AW, van den Bergh H and Dyson PJ*, Synthesis and characterization of a new class of anti-angiogenic agent based on ruthenium clusters, Scientific Reports, 3; 1485, 2013. (IF 5.08)
  • van Beijnum JR, Nowak-Sliwinska P, Van den Boezem E, Hautvast P, Buurman WA and Griffioen AW*, Tumor angiogenesis is enforced by autocrine regulation of high-mobility group box 1, Oncogene, 17;32(3):363-74, 2013. (IF 6.37)
  • Nowak-Sliwinska P*, Weiss A, Sickenberg M and van den Bergh H, Photodynamic Therapy in Ophthalmology, in The Handbook of Photomedicine, M. Hamblin and Y.Y Huang (Ed.), CRC Press, Taylor & Francis Group, ISBN 9781439884690, 451-465, 2013_._
  • Nowak-Sliwinska P*, Sickenberg M and van den Bergh H, Photodynamic therapy in Polyploidal Choroidal Vasculopathy, in Photodynamic Therapy: From Theory to Application, Abdel-Kader, Mahmoud H. (Ed.), Springer, ISBN 978-3-642-39628-1, 2013.

2012

  • Weiss A, van den Bergh H, Griffioen AW and Nowak-Sliwinska P*, Angiogenesis inhibition for improvement of photodynamic therapy; the revival of a promising idea, BBA Reviews on Cancer, 1826(1):53-70, 2012_._ (IF 9.93)
  • Piffaretti F, Novello AM, Kumar RS, Forte EN, Paulou C, van den Bergh H, Nowak-Sliwinska P and Wagnières G*, Real-time, in vivo measurement of tissular pO2 through the delayed fluorescence of endogenous protoporphyrin IX during photodynamic therapy, Journal of Biomedical Optics 17(11): 1150071-9, 2012_._ (IF 3.48)
  • Adar Y, Stark M, Bram EE, Nowak-Sliwinska P, van den Bergh H, Szewczyk G, Sarna T, Skladanowski A, Griffioen AW and Assaraf YG*, Imidazoacridinone-dependent lysosomal photodestruction: a pharmacological Trojan horse approach to eradicate multidrug resistant cancers, Cell Death Disease, doi:10.1038, 2012. (IF 5.53)
  • Griffioen AW, Mans L, de Graaf AM, Nowak-Sliwinska P, Bosch S, de Hoog C, Dellemijn T, Vyth-Dreese F, Jonasch E and Bex A*, Preoperative sunitinib treatment of RCC patients inhibits angiogenesis in the primary tumor; rapid angiogenesis onset after discontinuation of treatment, Clinical Cancer Research, 18(14):1-11, 2012. (IF 8.1)
  • Nowak-Sliwinska P*, Storto M, Cataudella T, Ballini JP, Gatz R, Giorgio M, van den Bergh H, Plyte S and Wagnières G, Study of the anti-angiogenic effects induced by the small molecule GNX-686, Microvascular Research, 83: 105-110, 2012. (IF 2.98)
  • Nowak-Sliwinska P*, Weiss A, van Beijnum JR, Wong T, Lovisa B, Ballini JP, van den Bergh H and Griffioen AW, Angiostatic kinase inhibitors to sustain photodynamic angio-occlusion, Journal of Cellular and Molecular Medicine, 16(7):1553-62, 2012_._ (IF 4.12)
  • Reuwer AQ, Nowak-Sliwinska P, Mans L, van der Loos CM, von der Thüsen JH, Twickler ThB, Spek AC, Goffin V, Griffioen AW and Borensztajn KS*, Prolactin induces angiogenesis through stimulation of endothelial cell migration, Journal of Cellular and Molecular Medicine, 16(9):2035-2048, 2012. (IF. 4.12)
  • Nowak-Sliwinska P*, Anti-angiogenic treatment for exudative age-related macular degeneration: new strategies are underway, Current Angiogenesis, 1(4): 318-334, 2012. Invited review.

2011

  • Nowak-Sliwinska P*, van Beijnum JR, Casini A, Nazarov A, Wagnières G, van den Bergh H, Dyson PJ and Griffioen AW. Organometallic ruthenium (II) compounds with anti-angiogenesis activity_,_ Journal of Medicinal Chemistry, 54(11): 3895-3902, 2011. (IF. 5.23)

2010

  • Nowak-Sliwinska P*, van Beijnum JR, van Berkel M, van den Bergh H and Griffioen AW, Vascular regrowth following photodynamic therapy in the chicken embryo chorioallantoic membrane; Angiogenesis, 13(4): 281-292, 2010. (IF. 6.06)
  • Lim S, Nowak-Sliwinska P, Kamarulzaman FA, van den Bergh H, Wagnières G and Lee H*, The neovessel occlusion efficacy of 151-hydroxypurpurin-7-lactone dimethyl ester induced with photodynamic therapy; Photochemistry and Photobiology, 86(2):397-402, 2010. (IF 2.40)     
  • Nowak-Sliwinska P*, Wagnières G, van den Bergh H and Griffioen AW, Angiostasis induced vascular normalization can improve photodynamic therapy; Cellular and Molecular Life Sciences, 67(9): 1559-60, 2010. (IF. 6.57)
  • Lim S, Thivierge C, Nowak-Sliwinska P, Han J, van den Bergh H, Wagnières G, Burgess K and Lee H*, In vitro and in vivo photo-cytotoxicity of BODIPY derivatives for photodynamic therapy; Journal of Medicinal Chemistry, 53(7): 2865-74_,_ 2010. (IF 5.23)
  • Nowak-Sliwinska P*, Ballini JP, Wagnières G and van den Bergh H, Processing of fluorescence angiograms for the quantification of vascular effects induced by anti-angiogenic agents in the CAM model, Microvascular Research, 79:21-28, 2010. (IF 2.98)